Characterizing dynamic changes of plasma cell-free Echinococcus granulosus DNA before and after cystic echinococcosis treatment initiation

Over one million people are living with cystic echinococcosis (CE) and alveolar echinococcosis (AE). For CE, long-term albendazole treatment is often needed, which requires regular follow-up. Follow-up is mainly through imaging which is insensitive to subtle changes and subjective to experience. We...

Full description

Saved in:

Bibliographic Details
Published in:	Genomics (San Diego, Calif.) Vol. 113; no. 2; pp. 576 - 582
Main Authors:	Zhao, Yanping, Gongsang, Quzhen, Ji, Jingkai, Li, Junhua, Qi, Fahai, Li, Jiandong, Qiangba, Gezhen, Danzeng, Wangmu, Chen, Fang, Zhou, Hongcheng, Huasang, Yin, Jiefang, Pei, Na, Xie, Jiandan, Cai, Huimin, Asan, Pang, Huasheng, Li, Jingzhong, Chen, Weijun, Li, Bin
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-03-2021
Subjects:	Adolescent Adult Albendazole - therapeutic use Animals Anticestodal Agents - therapeutic use Cell-free DNA Cell-Free Nucleic Acids - blood Cystic echinococcosis DNA, Helminth - blood Drug therapy Echinococcosis - blood Echinococcosis - drug therapy Echinococcosis - parasitology Echinococcus granulosus Echinococcus granulosus - genetics Echinococcus granulosus - pathogenicity Female High-throughput sequencing Humans Male Middle Aged Cell-free DNA Cystic echinococcosis High-throughput sequencing Drug therapy Echinococcus granulosus
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Over one million people are living with cystic echinococcosis (CE) and alveolar echinococcosis (AE). For CE, long-term albendazole treatment is often needed, which requires regular follow-up. Follow-up is mainly through imaging which is insensitive to subtle changes and subjective to experience. We investigated the changes of Echinococcus granulosus (Eg) cell-free DNA (cfDNA) in plasma of CE patients before and after albendazole treatment to evaluate its potential as an objective marker for treatment follow-up. Plasma samples of nine CE patients were collected before and after treatment. We identified Eg cfDNA from every sample through high-throughput sequencing. Eg cfDNA concentration and fragment length increased significantly after the treatment period. Ultrasound examination before and after the treatment initiation reflected the drug effects to a certain extent, as the cyst size of four patients reduced. Our findings indicated that Eg cfDNA from plasma could be a potential marker in the monitoring of CE treatment. •Over 1,000,000 people are living with echinococcosis (mostly cystic echinococcosis).•For CE, long-term albendazole treatment is often needed with regular monitoring.•Monitoring through imaging is not objective and fails to identify subtle changes.•Echinococcus granulosus (Eg) cfDNA in CE patients' plasma changed after treatment.•Eg cfDNA in CE patients' plasma could be a potential marker in monitoring treatment.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0888-7543 1089-8646
DOI:	10.1016/j.ygeno.2020.12.035